MetrioPharm AG has published financial figures 2008

MetrioPharm AG / Final Results

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this
announcement.
----------------------------------------------------------------------

MetrioPharm AG has published financial figures 2008


Zurich, 8th of June 2009: The Swiss MetrioPharm AG (WKN: A0MLMB; ISIN:
CH0029188817) has published its audited financial figures for 2008
according to the International Financial Reporting Standards (IFRS).

The business of MetrioPharm AG has developed according to the forecast in
the business year 2008. Business activities focused on the further
development of the licensed active pharmaceutical ingredients (API) and the
contact to potential licensees. Substantial advances in the research and
developmental program of MP1021 were achieved. With the licensing of
Etomoxir as well as following substances the product pipeline was expanded
and first contacts to possible licensees were made.

According to its business model MetrioPharm AG did not generate revenuesin
2008. Costs stayed within the budget as approved by the board. Especially
the costs for the synthesis of MP1021, which was achieved faster than
expected, were lower than initially predicted.  The operational result
amounts to CHF -3.5 millions (previous year: CHF -2.1 millions) and the
annual loss amounts to CHF -3,6 millions (previous year: CHF -2.1
millions).

MetrioPharm AG as a developer of pharmaceuticals expects to generate
revenues from licenses. Currently, the company holds several patents and
exclusive licences for the drugs MP1021 and Etomoxir. Further patent
applications are currently in process.

As to the accounting date of December 31st 2008 MetrioPharm AG reports a
total of CHF 7.2 millions (31st December 2007: CHF 8.6 millions). The
equity accounts for CHF 2,4 millions (December 31st 2007: CHF 6.0
millions). The short-term external finance increased to CHF 1.0 million
(December 31st 2007: CHF 0.7 millions). The long-term external finance also
increased to CHF 3.8 million (December 31st, 2007: CHF 1.9 millions). The
intangible assets amounted to CHF 6.9 millions (December 31st 2007: CHF 7.4
millions).

'As developer of promising candidate drugs we focus on the development and
registration of drugs in advanced stages, for which there is already
clinical evidence for efficacy in humans. The advantage of our business
model is the significantly reduced developmental risk compared to a
completely new drug substance. In addition, our business model results in
reduced time and costs', explained Dr. Brysch, president of the board of
MetrioPharm AG. 'Because of the positive developments in the research and
developmental program of MetrioPharm AG, especially for MP1021, we are
confident about our further progress. The validity of our business
strategy, with regard to the market needs, is reflected by widespread
interest in our lead-substance MP1021 from the pharmaceutical industry. The
already existing contacts to potential licensees will be intensified.
Specifically we intend to start out-licensing negotiations early in 2010.
With these activities we are approx. one year ahead of our original
schedule for out-licensing', says Dr. Brysch.

With immediate effect the annual report 2008 of the MetrioPharm AG is
available for download on the MetrioPharm-Homepage
http://www.metriopharm.com under 'Investor Relations'.


About MetrioPharm AG:
MetrioPharm AG is a biotechnology company which focuses on the development
and registration of small-molecular drugs in advanced developmental stages,
for which there is already clinical evidence for efficacy in humans.


Company Contact:
MetrioPharm AG
Neuendorfstrasse 20B
16761 Hennigsdorf
www.metriopharm.com
T. +49 (0) 3302 20 234 02
F. +49 (0) 3302 20 234 99
info@metriopharm.com

Investor Relations Contact:
GFEI Gesellschaft für Effekteninformation mbH
Hamburger Allee 26-28
60486 Frankfurt am Main
www.gfei.de
T. +49 (0) 69 743 037 00
F. +49 (0) 69 743 037 22
metriopharm@gfei.de


08.06.2009  Financial News transmitted by DGAP
----------------------------------------------------------------------